Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | STAT6 | P42226 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.33 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6155965 | 0.87 | LMNA (0.34) | SIGMAR1LMNATSHRSLC22A2SLC22A1 | |
| SCHEMBL8221572 | 0.78 | THRB (0.40) | SIGMAR1LMNATSHRSLC22A2SLC22A1 | |
| SCHEMBL6155972 | 0.75 | SIGMAR1 (0.39) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL28880587 | 0.73 | TGM2 (0.36) | TSHRTHRBEPHX2ALDH1A1 | |
| SCHEMBL9115097 | 0.67 | EPHX2 (0.54) | SIGMAR1EPHX2 | |
| Hydrochloric Acid SCHEMBL9115349 | 0.66 | SIGMAR1 (0.55) | SIGMAR1EPHX2 | |
| SCHEMBL12837664 | 0.66 | EPHX2 (0.34) | SIGMAR1EPHX2 | |
| SCHEMBL6158216 | 0.65 | EPHX2 (0.33) | EPHX2 | |
| SCHEMBL1497395 | 0.65 | LMNA (0.43) | SIGMAR1LMNATSHRSLC22A2SLC22A1 | |
| Hydrochloric Acid SCHEMBL2807432 | 0.63 | LMNA (0.46) | SIGMAR1LMNATSHRSLC22A2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073631-A1 | ANTIVIRAL AND ANTIMICROBIAL COMPOUNDS | VYMED CORPORATION (US) | 2014-03-13 | — | — | US | disclosed |
| EP-1406619-A4 | ANTIVIRAL AND ANTIMICROBIAL GUANIDINE OR BIGUANIDINE DERIVATIVES | SHETTY B VITHAL (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040132993-A1 | Antiviral and antimicrobial guanidine or biguanidine derivatives | SHETTY B VITHAL (US) | 2004-07-08 | — | — | US | disclosed |
| EP-1406619-A1 | ANTIVIRAL AND ANTIMICROBIAL GUANIDINE OR BIGUANIDINE DERIVATIVES | Shetty, B. Vithal (US) | 2004-04-14 | — | — | EP | disclosed |
| US-6699989-B1 | HUMAN T-CELL LEUKEMIA/LYMPHOMA VIRUS (HTLV) AND LYMPHADENOPATHY ASSOCIATED VIRUS TREATMENT; AIDS | VYMED CORPORATION | 2004-03-02 | — | — | US | disclosed |
| WO-2002017916-A1 | ANTIVIRAL AND ANTIMICROBIAL GUANIDINE OR BIGUANIDINE DERIVATIVES | SHETTY B VITHAL (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073631-A1 | ANTIVIRAL AND ANTIMICROBIAL COMPOUNDS | GDA, GMPS, GANC | SIGMAR1 1306/4885LMNA 3327/4885TSHR 4815/4885 |
| US-20040132993-A1 | Antiviral and antimicrobial guanidine or biguanidine derivatives | GMPS, GDA, GANC | SIGMAR1 1326/4885LMNA 2599/4885TSHR 4774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.